This positions dorzagliatin as an attractive candidate for the management of PI3K inhibitor-induced hyperglycemia, with the potential to sustain the therapeutic efficacy of PI3Ki without the drawbacks associated with insulin feedback. Here, PIK3CA is linked to Hyperglycemia.